{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T16:10:16Z","timestamp":1770999016118,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2011,10,11]],"date-time":"2011-10-11T00:00:00Z","timestamp":1318291200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Qual Life Res"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1007\/s11136-011-0034-1","type":"journal-article","created":{"date-parts":[[2011,10,10]],"date-time":"2011-10-10T14:46:23Z","timestamp":1318257983000},"page":"1255-1266","source":"Crossref","is-referenced-by-count":12,"title":["The anemia impact measure (AIM): development and content validation of a patient-reported outcome measure of anemia symptoms and symptom impacts in cancer patients receiving chemotherapy"],"prefix":"10.1007","volume":"21","author":[{"given":"Leah","family":"Kleinman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katy","family":"Benjamin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hema","family":"Viswanathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Stoeckl","family":"Mattera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Bosserman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas W.","family":"Blayney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis A.","family":"Revicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,10,11]]},"reference":[{"issue":"19","key":"34_CR1","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/jnci\/91.19.1616","volume":"91","author":"JE Groopman","year":"1999","unstructured":"Groopman, J. E., & Itri, L. M. (1999). Chemotherapy-induced anemia in adults: Incidence and treatment. Journal of the National Cancer Institute, 91(19), 1616\u20131634.","journal-title":"Journal of the National Cancer Institute"},{"key":"34_CR2","doi-asserted-by":"crossref","unstructured":"Knight, K., Wade, S. & Balducci, L. (2004). Prevalence and outcomes of anemia in cancer: A systematic review of the literature. Am J Med, 116(Suppl 7A), 11S\u201326S.","DOI":"10.1016\/j.amjmed.2003.12.008"},{"issue":"8","key":"34_CR3","first-page":"973","volume":"89","author":"F Merli","year":"2004","unstructured":"Merli, F., Bertini, M., Luminari, S., Mozzana, R., Berte, R., Trottini, M., et al. (2004). Quality of life assessment in elderly patients with aggressive non-Hodgkin\u2019s Lymphoma treated with anthracycline-containing regimens. Report of a prospective study by the Intergruppo Italiano Linfomi. Haematologica, 89(8), 973\u2013978.","journal-title":"Haematologica"},{"key":"34_CR4","doi-asserted-by":"crossref","unstructured":"Pujade-Lauraine, E. & Gascon, P. (2004). The burden of anaemia in patients with cancer. Oncology, 67(Suppl 1), 1\u20134.","DOI":"10.1159\/000080702"},{"key":"34_CR5","doi-asserted-by":"crossref","unstructured":"Bokemeyer, C. & Foubert, J. (2004). Anemia impact and management: focus on patient needs and the use of erythropoietic agents. Semin Oncol, 31(3 Suppl 8), 4\u201311.","DOI":"10.1053\/j.seminoncol.2004.04.003"},{"issue":"5","key":"34_CR6","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1634\/theoncologist.12-5-584","volume":"12","author":"R Boccia","year":"2007","unstructured":"Boccia, R., Lillie, T., Tomita, D., & Balducci, L. (2007). The effectiveness of darbepoetin alfa administered every 3\u00a0weeks on hematologic outcomes and quality of life in older patients with chemotherapy-induced anemia. Oncologist, 12(5), 584\u2013593.","journal-title":"Oncologist"},{"issue":"2","key":"34_CR7","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2165\/00019053-200523020-00009","volume":"23","author":"E Berndt","year":"2005","unstructured":"Berndt, E., Crown, W., Kallich, J., Long, S., Song, X., & Lyman, G. H. (2005). The impact of anaemia and its treatment on employee disability and medical costs. Pharmacoeconomics, 23(2), 183\u2013192.","journal-title":"Pharmacoeconomics"},{"key":"34_CR8","unstructured":"Kallich, J. D., Tchekmedyian, N. S., Damiano, A. M., Shi, J., Black, J. T. & Erder, M. H. (2002). Psychological outcomes associated with anemia-related fatigue in cancer patients. Oncology (Williston Park), 16(9 Suppl 10), 117\u2013124."},{"issue":"4","key":"34_CR9","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jpainsymman.2005.08.013","volume":"31","author":"TJ Littlewood","year":"2006","unstructured":"Littlewood, T. J., Kallich, J. D., San Miguel, J., Hendricks, L., & Hedenus, M. (2006). Efficacy of darbepoetin alfa in alleviating fatigue and the effect of fatigue on quality of life in anemic patients with lymphoproliferative malignancies. Journal of Pain and Symptom Management, 31(4), 317\u2013325.","journal-title":"Journal of Pain and Symptom Management"},{"issue":"6","key":"34_CR10","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/annonc\/mdh235","volume":"15","author":"D Cella","year":"2004","unstructured":"Cella, D., Kallich, J., McDermott, A., & Xu, X. (2004). The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Annals of Oncology, 15(6), 979\u2013986.","journal-title":"Annals of Oncology"},{"issue":"5","key":"34_CR11","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2165\/00019053-200523050-00009","volume":"23","author":"E Berndt","year":"2005","unstructured":"Berndt, E., Kallich, J., McDermott, A., Xu, X., Lee, H., & Glaspy, J. (2005). Reductions in anaemia and fatigue are associated with improvements in productivity in cancer patients receiving chemotherapy. Pharmacoeconomics, 23(5), 505\u2013514.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"34_CR12","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1524-4733.2005.03089.x","volume":"8","author":"GH Lyman","year":"2005","unstructured":"Lyman, G. H., Berndt, E. R., Kallich, J. D., Erder, M. H., Crown, W. H., Long, S. R., et al. (2005). The economic burden of anemia in cancer patients receiving chemotherapy. Value Health, 8(2), 149\u2013156.","journal-title":"Value Health"},{"key":"34_CR13","unstructured":"Seidenfeld, J., Piper, M., Bohlius, J., Weingart, O., Trelle, S., Engert, A., et al. (2006). Comparative effectiveness of epoetin and darbepoetin for managing anemia in patients undergoing cancer treatment. Comparative effectiveness review no. 3. (Prepared by Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-based Practice Center under Contract No. 290-02-0026). Available at: http:\/\/www.effectivehealthcare.ahrq.gov\/reports\/final.cfm ."},{"issue":"2","key":"34_CR14","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000067766","volume":"64","author":"A Bamias","year":"2003","unstructured":"Bamias, A., Aravantinos, G., Kalofonos, C., Timotheadou, N., Siafaka, V., Vlahou, I., et al. (2003). Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human Erythropoietin (rHuEpo): A prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group. Oncology, 64(2), 102\u2013110.","journal-title":"Oncology"},{"issue":"7","key":"34_CR15","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/sj.bjc.6600801","volume":"88","author":"M Boogaerts","year":"2003","unstructured":"Boogaerts, M., Coiffier, B., & Kainz, C. (2003). Impact of epoetin beta on quality of life in patients with malignant disease. British Journal of Cancer, 88(7), 988\u2013995.","journal-title":"British Journal of Cancer"},{"issue":"11","key":"34_CR16","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.2001.19.11.2865","volume":"19","author":"TJ Littlewood","year":"2001","unstructured":"Littlewood, T. J., Bajetta, E., Nortier, J. W., Vercammen, E., & Rapoport, B. (2001). Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology, 19(11), 2865\u20132874.","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"34_CR17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00280-006-0251-4","volume":"59","author":"J Castro de","year":"2007","unstructured":"de Castro, J., Ordonez, A., Isla, D., Sanchez, A., Arrivi, A., Manzano, J. L., et al. (2007). Early intervention with epoetin beta prevents severe anaemia in patients with solid tumours receiving platinum-based chemotherapy: Results of the NeoPrevent study. Cancer Chemotherapy and Pharmacology, 59(1), 35\u201342.","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"11","key":"34_CR18","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2001.19.11.2875","volume":"19","author":"JL Gabrilove","year":"2001","unstructured":"Gabrilove, J. L., Cleeland, C. S., Livingston, R. B., Sarokhan, B., Winer, E., & Einhorn, L. H. (2001). Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. Journal of Clinical Oncology, 19(11), 2875\u20132882.","journal-title":"Journal of Clinical Oncology"},{"issue":"15","key":"34_CR19","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1200\/JCO.2005.03.8570","volume":"24","author":"J Glaspy","year":"2006","unstructured":"Glaspy, J., Vadhan-Raj, S., Patel, R., Bosserman, L., Hu, E., Lloyd, R. E., et al. (2006). Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. Journal of Clinical Oncology, 24(15), 2290\u20132297.","journal-title":"Journal of Clinical Oncology"},{"key":"34_CR20","unstructured":"Cella, D. (1997). The Functional Assessment of Cancer Therapy-Anemia (FACT-An) scale: A new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol, 34(3 Suppl 2), 13\u201319."},{"issue":"2","key":"34_CR21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0885-3924(96)00274-6","volume":"13","author":"SB Yellen","year":"1997","unstructured":"Yellen, S. B., Cella, D. F., Webster, K., Blendowski, C., & Kaplan, E. (1997). Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. Journal of Pain and Symptom Management, 13(2), 63\u201374.","journal-title":"Journal of Pain and Symptom Management"},{"issue":"1","key":"34_CR22","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.genhosppsych.2006.10.005","volume":"29","author":"TT Levin","year":"2007","unstructured":"Levin, T. T., Riskind, J. H., & Li, Y. (2007). Looming threat-processing style in a cancer cohort. General Hospital Psychiatry, 29(1), 32\u201338.","journal-title":"General Hospital Psychiatry"},{"issue":"2","key":"34_CR23","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.lungcan.2006.05.002","volume":"53","author":"RL Manser","year":"2006","unstructured":"Manser, R. L., Wright, G., Byrnes, G., Hart, D., Conron, M., Carter, R., et al. (2006). Validity of the Assessment of Quality of Life (AQoL) utility instrument in patients with operable and inoperable lung cancer. Lung Cancer, 53(2), 217\u2013229.","journal-title":"Lung Cancer"},{"issue":"12","key":"34_CR24","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1200\/JCO.2004.10.020","volume":"23","author":"TE Witzig","year":"2005","unstructured":"Witzig, T. E., Silberstein, P. T., Loprinzi, C. L., Sloan, J. A., Novotny, P. J., Mailliard, J. A., et al. (2005). Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. Journal of Clinical Oncology, 23(12), 2606\u20132617.","journal-title":"Journal of Clinical Oncology"},{"issue":"235","key":"34_CR25","first-page":"65132","volume":"74","author":"Food and Drug Administration (FDA)","year":"2009","unstructured":"Food and Drug Administration (FDA). (2009). Guidance for industry on patient-reported outcome measures: Use in medical product development to support labeling claims. Federal Register, 74(235), 65132\u201365133.","journal-title":"Federal Register"},{"issue":"8","key":"34_CR26","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1023\/A:1008996223999","volume":"9","author":"DA Revicki","year":"2000","unstructured":"Revicki, D. A., Osoba, D., Fairclough, D., Barofsky, I., Berzon, R., Leidy, N. K., et al. (2000). Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Quality of Life Research, 9(8), 887\u2013900.","journal-title":"Quality of Life Research"},{"key":"34_CR27","doi-asserted-by":"crossref","unstructured":"Patrick, D. L., Burke, L. B., Powers, J. H., Scott, J. A., Rock, E. P., Dawisha, S., et al. (2007). Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health, 10(Suppl 2), S125\u2013137.","DOI":"10.1111\/j.1524-4733.2007.00275.x"},{"key":"34_CR28","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/ddr.20077","volume":"67","author":"P Marquis","year":"2006","unstructured":"Marquis, P., Arnould, B., Acquadro, C., & Roberts, W. M. (2006). Patient-reported outcomes and health-related quality of life in effectiveness studies: pros and cons. Drug Development Research, 67, 193\u2013201.","journal-title":"Drug Development Research"},{"issue":"2","key":"34_CR29","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1046\/j.1524-4733.1999.02210.x","volume":"2","author":"NK Leidy","year":"1999","unstructured":"Leidy, N. K., Revicki, D. A., & Geneste, B. (1999). Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health, 2(2), 113\u2013127.","journal-title":"Value Health"},{"issue":"6","key":"34_CR30","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.cct.2004.09.003","volume":"25","author":"RJ Willke","year":"2004","unstructured":"Willke, R. J., Burke, L. B., & Erickson, P. (2004). Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels. Controlled Clinical Trials, 25(6), 535\u2013552.","journal-title":"Controlled Clinical Trials"},{"issue":"5702","key":"34_CR31","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1126\/science.1103572","volume":"306","author":"D Kahneman","year":"2004","unstructured":"Kahneman, D., Krueger, A. B., Schkade, D. A., Schwarz, N., & Stone, A. A. (2004). A survey method for characterizing daily life experience: The day reconstruction method. Science, 306(5702), 1776\u20131780.","journal-title":"Science"},{"key":"34_CR32","volume-title":"SF-12: How to score the SF-12 physical and mental health summary scales","author":"JE Ware","year":"1995","unstructured":"Ware, J. E., Kosinski, M., & Keller, S. D. (1995). SF-12: How to score the SF-12 physical and mental health summary scales. Boston, MA: The Health Institute, New England Medical Center."},{"issue":"11","key":"34_CR33","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0895-4356(98)00109-7","volume":"51","author":"B Gandek","year":"1998","unstructured":"Gandek, B., Ware, J. E., Aaronson, N. K., Apolone, G., Bjorner, J. B., Brazier, J. E., et al. (1998). Cross-validation of item selection and scoring for the SF-12 health survey in nine countries: Results from the IQOLA project international quality of life assessment. Journal of Clinical Epidemiology, 51(11), 1171\u20131178.","journal-title":"Journal of Clinical Epidemiology"},{"key":"34_CR34","unstructured":"World Health Organization. (1993). Indicators and strategies for iron deficiency and anemia programmes (pp. 6\u201310). Report of the WHO\/UNICEF\/UNU Consultation. Geneva, Switzerland."},{"key":"34_CR35","unstructured":"Woolf, N. (2007). Best practices: a little structure in your codes. Atlas.ti Newsletter. Available at: http:\/\/www.atlasti.com\/downloads\/ATLASti_Newsletter_2007_01.pdf ."},{"key":"34_CR36","volume-title":"Assessing quality of life in clinical trials","author":"RD Hays","year":"2005","unstructured":"Hays, R. D., & Revicki, D. A. (2005). Reliability and validity, including responsiveness. In P. Fayers & R. D. Hays (Eds.), Assessing quality of life in clinical trials. New York: Oxford University Press."},{"key":"34_CR37","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/oso\/9780198527695.003.0002","volume-title":"Assessing quality of life in clinical trials","author":"E McColl","year":"2005","unstructured":"McColl, E. (2005). Developing questionnaires. In P. Fayers & R. Hays (Eds.), Assessing quality of life in clinical trials (pp. 9\u201323). New York: Oxford University Press."},{"key":"34_CR38","volume-title":"Outcomes assessment in cancer: measures, methods and applications","author":"G Willis","year":"2004","unstructured":"Willis, G., Reeve, B., & Barofsky, I. (2004). The use of cognitive interviewing techniques in quality-of-life and patient-reported outcomes assessment. In J. Lipscomb, C. Gotay, & C. Synder (Eds.), Outcomes assessment in cancer: measures, methods and applications. Cambridge, UK: Cambridge University Press."},{"issue":"2","key":"34_CR39","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/cncr.10245","volume":"94","author":"D Cella","year":"2002","unstructured":"Cella, D., Lai, J. S., Chang, C. H., Peterman, A., & Slavin, M. (2002). Fatigue in cancer patients compared with fatigue in the general United States population. Cancer, 94(2), 528\u2013538.","journal-title":"Cancer"},{"key":"34_CR40","doi-asserted-by":"crossref","unstructured":"Harper, P. & Littlewood, T. (2005). Anaemia of cancer: impact on patient fatigue and long-term outcome. Oncology, 69(Suppl 2), 2\u20137.","DOI":"10.1159\/000088282"},{"issue":"2","key":"34_CR41","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/cncr.20777","volume":"103","author":"DJ Brown","year":"2005","unstructured":"Brown, D. J., McMillan, D. C., & Milroy, R. (2005). The correlation between fatigue, physical function, the systemic inflammatory response, and psychological distress in patients with advanced lung cancer. Cancer, 103(2), 377\u2013382.","journal-title":"Cancer"},{"issue":"1","key":"34_CR42","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/annonc\/mdj038","volume":"17","author":"A Mancuso","year":"2006","unstructured":"Mancuso, A., Migliorino, M., De Santis, S., Saponiero, A., & De Marinis, F. (2006). Correlation between anemia and functional\/cognitive capacity in elderly lung cancer patients treated with chemotherapy. Annals of Oncology, 17(1), 146\u2013150.","journal-title":"Annals of Oncology"},{"key":"34_CR43","unstructured":"Vogelzang, N. J., Breitbart, W., Cella, D., Curt, G. A., Groopman, J. E., Horning, S. J., et al. (1997). Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The fatigue coalition. Seminars in Hematology, 34(3 Suppl 2), 4\u201312."},{"issue":"3","key":"34_CR44","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1046\/j.1365-2141.2003.04448.x","volume":"122","author":"M Hedenus","year":"2003","unstructured":"Hedenus, M., Adriansson, M., San Miguel, J., Kramer, M. H., Schipperus, M. R., Juvonen, E., et al. (2003). Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: A randomized, double-blind, placebo-controlled study. British Journal Haematology, 122(3), 394\u2013403.","journal-title":"British Journal Haematology"},{"issue":"16","key":"34_CR45","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1093\/jnci\/94.16.1211","volume":"94","author":"J Vansteenkiste","year":"2002","unstructured":"Vansteenkiste, J., Pirker, R., Massuti, B., Barata, F., Font, A., Fiegl, M., et al. (2002). Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. Journal of the National Cancer Institute, 94(16), 1211\u20131220.","journal-title":"Journal of the National Cancer Institute"},{"issue":"14","key":"34_CR46","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1200\/JCO.2007.15.0748","volume":"26","author":"R Pirker","year":"2008","unstructured":"Pirker, R., Ramlau, R. A., Schuette, W., Zatloukal, P., Ferreira, I., Lillie, T., et al. (2008). Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide. Journal of Clinical Oncology, 26(14), 2342\u20132349.","journal-title":"Journal of Clinical Oncology"},{"key":"34_CR47","unstructured":"Cella, D., Lai, J. S., & Stone, A. (2010). Self-reported fatigue: One dimension or more? Lessons from the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) questionnaire. Support Care Cancer."},{"key":"34_CR48","unstructured":"Lai, J.-S., & Chen, W.-H. (2006). Fatigue archival analysis report prepared for: The PROMIS SCC analysis team. Available at: http:\/\/www.nihpromis.org\/Data%20Analysis\/FatigueArchivalAnalysisReport.doc ."},{"key":"34_CR49","doi-asserted-by":"crossref","unstructured":"Ryan, J. L., Carroll, J. K., Ryan, E. P., Mustian, K. M., Fiscella, K. & Morrow, G. R. (2007). Mechanisms of cancer-related fatigue. Oncologist, 12(Suppl 1), 22\u201334.","DOI":"10.1634\/theoncologist.12-S1-22"}],"container-title":["Quality of Life Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-011-0034-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11136-011-0034-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-011-0034-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T12:58:03Z","timestamp":1713013083000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11136-011-0034-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,11]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["34"],"URL":"https:\/\/doi.org\/10.1007\/s11136-011-0034-1","relation":{},"ISSN":["0962-9343","1573-2649"],"issn-type":[{"value":"0962-9343","type":"print"},{"value":"1573-2649","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,11]]}}}